Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05894382

Double Helix Design Defocus Lens Spectacle (RACE) for Myopia Control

This study uses 1.585 double helix defocus lens PC lenses with a unique optical design that includes a globally coherent visible area and complementary left and right helices that can form clear images. In addition, the helical arrangement and reduced slit area can generate defocusing signals, inhibiting the development of myopia. Therefore, based on previous research, this study plans to evaluate the safety and effectiveness of 1.585 double helix defocus lens PC frame eyeglasses in controlling the progression of myopia in children and adolescents through a randomized controlled clinical trial.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

6 year–13 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Xiangui He

Shanghai, Shanghai Municipality, 201103, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Race: Chinese children and adolescents.
  • Age 6-13 years, gender unrestricted.
  • Cycloplegic refraction SER: -0.75DS~-5.0DS in both eyes.
  • Best corrected visual acuity of both eyes reaches 1.0 (0.00 logMAR 6/6).
  • Refractive astigmatism and astigmatism are no more than 1.5D.
  • During the study period, willing to wear glasses provided by the researcher only (>10 hours) and without additional interventions.
  • Willing to be randomly assigned.
  • Able to sign an informed consent form with the accompaniment and understanding of parents or guardians.

Exclusion criteria

  • Allergic or intolerant to medications used for ciliary muscle paralysis.
  • Received any nearsightedness treatment such as atropine, rigid gas permeable contact lens, bifocal/progressive lens, red light therapy, or acupuncture within 30 days before the study.
  • Received defocus lenses for nearsightedness treatment in the past.
  • Diagnosed with any eye disease other than nearsightedness, including strabismus (esotropia greater than 8 prism diopters or exotropia greater than 12 prism diopters), corneal diseases, conjunctival or eyelid damage or other conditions (such as keratoconus, herpes simplex keratitis, etc.).
  • History of eye surgery (including strabismus correction surgery).
  • Eye or systemic diseases that might be associated with nearsightedness or its progression, such as Marfan syndrome, retinopathy of prematurity, diabetes, etc.
  • Anatomical or dermatological factors that may interfere with the wearing of spectacle frames.
  • Other reasons that the researcher deems inappropriate for the participant to be included in the study, such as excessively high expectations for the effectiveness of defocus lenses, or plans to use other nearsightedness intervention strategies simultaneously with the study.

Treatment and study plan

Double Helix Design Defocus Lens Spectacle (RACE)

Device

Double Helix Design Defocus Lens Spectacle wearing more than 10h/day.

single-vision spetacle lens

Device

single-vision spetacle lens wearing more than 10h/day.

Primary outcomes

  1. Spherical Equivalent change

    Time frame: 1 year

    cycloplegic SE change

Secondary outcomes

  1. Axial Length change

    Time frame: 1 year

  2. Visual Acuity change

    Time frame: 1 year

Sponsors and collaborators

Lead sponsor

Shanghai Eye Disease Prevention and Treatment Center

Other

Registry information

Official study title

A Randomized Controlled Study on the Effectiveness, Safety and Adaptability of Double Helix Design Defocus Lens Spectacle Frames for Correction of Visual Acuity in Children and Adolescents, and Control of Myopia.

Important dates

Study start
2023
Primary completion
2026
Study completion
2026
First posted
Jun 8, 2023
Registry last updated
Dec 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.